CDC suggests link between Opana and HIV outbreak; NICE gives final nod to Xolair for hives;

@FiercePharma: ICYMI yesterday: GSK's Advair dogged again as Mylan launches first bioequivalent copy in U.K. Article | Follow @FiercePharma

@EricPFierce: Mylan recalls more injected cancer drugs it made for Pfizer at its Agila plants in India. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: Could an $18.9B Shire bid convince Actelion to ditch its independence? More | Follow @CarlyHFierce

> Centers for Disease Control and Prevention officials suggest that Endo International's ($ENDP) abuse-deterrent version of the pain drug Opana has played a role in an outbreak of HIV spread by sharing needles. Report

> Cost-effectiveness watchdogs at England's National Institute for Health and Care Excellence (NICE) gave Novartis' ($NVS) Xolair drug its final blessing as a treatment for allergy-related hives. Report

> Two former Merck & Co. ($MRK) scientists, who accuse the company of falsifying data about its mumps vaccine in a whistleblower lawsuit, say the company is refusing to disclose key information about its efficacy. Report

> Ironwood Pharmaceuticals ($IRWD) said it plans to launch a $300 million debt offering. Release

> Abbott ($ABT) India launched a liver health campaign to encourage hepatitis C testing and treatment. Report

Medical Device News

@FierceMedDev: ICYMI from @StacyALawrence: Intarcia readies for FDA in 2016, reports detailed Ph III data for once-yearly diabetes implant. Report | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Medtronic, BD to collaborate on diabetes infusion set featuring enhanced insulin delivery. Story | Follow @VarunSaxena2

> Medtronic launches bariatric surgery tool to enable more consistent procedures. Story

> Outset Medical rounds up $91M to make dialysis options more attractive. News

Biotech News

@FierceBiotech: FDA asks experts to weigh in on PCSK9 drugs' market reach for Amgen, Regeneron/Sanofi. Report | Follow @FierceBiotech

@JohnCFierce: If I set up a biotech, treated 4 patients with depression with ketamine and then touted the results, would people buy my stock? $SAGE | Follow @JohnCFierce

@DamianFierce: Excellent feature about ClickHole. And an excellent feature on ClickHole | Follow @DamianFierce

> Biogen's Alzheimer's success has Roche on the verge of a redo. Item

> Illumina helps add a $37M Twist on DNA synthesis. More

> Sage gets a peek at success treating postpartum depression, and its shares soar. Story

> Sanofi's new diabetes drug is finally ready for FDA scrutiny. Article

Drug Delivery News

> Research group seeks to promote crystals as drug delivery, development tools. More

> Implanted device releases drugs to help determine cancer-killing course of action. Item

> Sebacia raises $8M, nears FDA submission of laser-activated microparticles for acne. News

> Braeburn's once-rejected implant to treat opioid abuse shown comparable to pills in pivotal trial. Story

> India's Cipla gets first FDA approval of oral pellet to treat HIV/AIDS in infants. Report

Pharma Manufacturing News

> Serious manufacturing issues tied to fungal contamination in NIH facility. News

> Mylan picks 3M to manufacture its generic Advair inhaler for U.K. market. Item

> Cardinal Health targets hospital sales with $1.1B bid for Harvard Drug Group. More

> Mylan expands recall of cancer meds made for Pfizer. Report

> AstraZeneca's manufacturing gets another boost with $125M Africa plant. Story

Pharma Asia News

> India's Sun says slow and steady on Ranbaxy plants, FDA on Wockhardt at odds with management. Item

> Complaints trickle in about higher drug prices in China after cap removal. Report

> China's 3SBio returns to market and pulls in $710.7M in HK IPO. More

> GSK, Sanofi hauled up by India's competition watchdog on vaccine tenders. Story

> Australia's Proteomics claims first predictive diabetic kidney disease diagnostic test. Article

And Finally... Colon cancer patients were more likely to have visited their doctors multiple times in the year before diagnosis than did people without cancer. Report

Suggested Articles

Novartis said it plans to use the complete response rate data for a U.S. filing in follicular lymphoma in 2021.

Sen. Elizabeth Warren asked the SEC to probe Kodak trades made before the Trump administration unveiled their drug supply deal—and $765M in funding.

Amarin's wild 2020 ride continues with plans to launch its cardiovascular med Vascepa in Europe without a bigger marketing partner.